Technique and outcome of autologous portal Y‐graft interposition for anomalous right portal veins in living donor liver transplantation

Shin Hwang, Sung‐Gyu Lee, Chul‐Soo Ahn, Ki‐Hun Kim, Deok‐Bog Moon, Tae‐Yong Ha, Gi‐Won Song, Dong‐Hwan Jung, Je‐Ho Ryu, Kyung‐Hoon Ko, Nam‐Kyu Choi, Kwan‐Woo Kim – 26 March 2009 – This study was intended to describe in detail the surgical technique and long‐term outcome of autologous portal vein (PV) Y‐graft interposition for adult living donor liver transplantation (LDLT). We assessed the outcome of 841 patients who underwent right lobe LDLT from January 2002 to December 2007 with respect to the reconstruction of double‐graft PVs.

Acute graft‐versus‐host disease after liver transplant: Novel use of etanercept and the role of tumor necrosis factor α inhibitors

Lena Thin, Gerry MacQuillan, Leon Adams, George Garas, Cynthia Seow, Paul Cannell, Bradley Augustson, Andrew Mitchell, Luc Delriveire, Gary Jeffrey – 26 March 2009 – Acute graft‐versus‐host disease following orthotopic liver transplantation is a rare but feared complication arising in 1% to 2% of cases with a dismal prognosis. It most often presents as fever, rash, and diarrhea with or without pancytopenia. Patients die from complications of marrow failure such as sepsis or bleeding. Because of its low incidence, there is no clear treatment protocol for this complication.

Post–liver transplant survival in hepatitis C patients is improving over time

Jacqueline G. O'Leary, Henry Randall, Nicholas Onaca, Linda Jennings, Göran B. Klintmalm, Gary L. Davis – 26 March 2009 – Outcomes after orthotopic liver transplantation for chronic hepatitis C have been reported to be worsening over the last 2 decades. We analyzed our center's experience over 15 years to identify trends in post–orthotopic liver transplantation survival in patients with and without hepatitis C virus infection.

Intrathecal morphine combined with intravenous patient‐controlled analgesia is an effective and safe method for immediate postoperative pain control in live liver donors

Justin Sangwook Ko, Soo Joo Choi, Mi Sook Gwak, Gaab Soo Kim, Hyun Joo Ahn, Jie Ae Kim, Tae Soo Hahm, Hyun Sung Cho, Kyoung Mi Kim, Jae Won Joh – 26 March 2009 – The healthy condition of living donors makes their tolerance to pain particularly low, and clinicians are often challenged to come up with an analgesic technique that is effective yet ensures donor safety. This study compared, in donor right hepatectomy, the efficacy and safety of preoperative intrathecal morphine (ITM) combined with intravenous patient‐controlled analgesia (IV‐PCA) with IV‐PCA alone.

Decision analysis model for hepatitis B prophylaxis one year after liver transplantation

Sammy Saab, Maggie Y. Ham, Michael A. Stone, Curtis Holt, Myron Tong – 26 March 2009 – In patients receiving orthotopic liver transplantation, hepatitis B recurrence rates have decreased significantly with the use of various methods for prophylaxis. At present, a combination of hepatitis B immunoglobulin (HBIG) and lamivudine is the standard of care, resulting in recurrence rates of 0% to 11%. Recent data suggest that the addition of adefovir to lamivudine is successful in treating patients with recurrent hepatitis B infection.

Sclerosing peritonitis and mortality after liver transplantation

Kristin Mekeel, Adyr Moss, Kunam Sudhakar Reddy, David Douglas, David Mulligan – 26 March 2009 – Sclerosing peritonitis describes the development of a peel or rind of fibrosis that spreads over the peritoneal surface and can lead to recalcitrant ascites, bowel obstruction, and sepsis. It is well described as a complication of peritoneal dialysis, especially with episodes of bacterial peritonitis. It is also a complication of end‐stage liver disease with ascites and liver transplantation.

Subscribe to